Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-25-274432
Filing Date
2025-11-10
Accepted
2025-11-10 16:42:33
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 18717
  Complete submission text file 0001193125-25-274432.txt   20772
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filed by) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703
Business Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703 919-908-2422
Pelthos Therapeutics Inc. (Subject) CIK: 0001919246 (see all company filings)

EIN.: 863335449 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-94460 | Film No.: 251466986
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)